The FDA has cleared Cordis' EMPIRA and EMPIRA NC RX PTCA dilatation catheters for the treatment of coronary artery disease. The U.S. launch is expected early next year. "The EMPIRA Balloon Catheters offer our most advanced technology designed to treat challenging coronary artery disease," explained Campbell Rogers, Cordis chief scientific officer, global head R&D. "Cordis worked closely with our physician-customers and incorporated their feedback into the design of these next generation devices." Cordis release